CSIMarket


Scpharmaceuticals Inc   (SCPH)
Other Ticker:  
 


 

Scpharmaceuticals Inc

SCPH's Financial Statements and Analysis



Scpharmaceuticals Inc increased third quarter of 2023 net loss per share of $-0.41 compare to net loss per share of $-0.37 recorded in the same quarter a year ago a decrease compare to $-0.36 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.41 $  4 Mill
$-0.04     $+4M    



Scpharmaceuticals Inc 's Revenue rose by 0 % in third quarter of 2023 (Sep 30 2023) year on year, to $4 million and advanced by 131.75 % sequentially.


Scpharmaceuticals Inc is Expected to report next financial results on March 21, 2024.

More on SCPH's Income Statement



Scpharmaceuticals Inc 's in thethird quarter of 2023 recorded net loss of $-15.634 million, an increase from net loss of $-10.162 million in III. Quarter a year ago.

Sequentially net loss advanced

More on SCPH's Growth

Scpharmaceuticals Inc Inventories
In Sep 30 2023 company's net cash and cash equivalents decreased by $-36 million


Scpharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Scpharmaceuticals Inc payed $ -1.44 cash per share, on a free-cash flow basis .

Book value fell by -22.65 % sequentially to $1.27 per share, -27.20% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 1.27 per share from $ 1.64.

Company issued 0.07 million shares or 0.18 % in Sep 30 2023.


More on SCPH's Dividends

 Market Capitalization (Millions) 219
 Shares Outstanding (Millions) 39
 Total Debt (Millions $) 38
 Revenue (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -50
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 2,191




Scpharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Scpharmaceuticals Inc had negative $ -1.44 cash flow per share, on a free-cash flow basis .

Book value fell by -22.65 % sequentially to $1.27 per share, -27.20% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 1.27 per share from $ 1.64.

Company issued 0.07 million shares or 0.18 % in Sep 30 2023.


More on SCPH's Balance Sheets

 Market Capitalization (Millions) 219
 Shares Outstanding (Millions) 39
 Total Debt (Millions $) 38
 Revenue (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -50
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 2,191
   


  News about Scpharmaceuticals Inc Earnings

Scpharmaceuticals Inc Generates $3.796 Million in Revenue in Third Quarter, Faces Net Shortfall in Earnings

Scpharmaceuticals Inc Reports Revenue of $3.796 Million in Third Quarter, Faces Net Shortfall in Earnings
Investors showed concern as Scpharmaceuticals Inc, a renowned pharmaceutical company, recently disclosed its third-quarter earnings for 2023. The quarter saw the company generate $3.796 million in revenue, providing some relief amid a challenging market environment. Despite this positive revenue figure, Scpharmaceuticals Inc faced a net shortfall of $-15.634 million, surpassing last year's deficit of $-10.162 million.
The larger net shortfall indicates that Scpharmaceuticals Inc has encountered significant setbacks, potentially impacting its overall financial performance. This shortfall may have ...

Scpharmaceuticals Inc Reveals Impressive Q2 2023 Revenue of $1.638 Million


Introduction
In the second quarter of the 2023 earnings season, SCPHarmaceuticals Inc (SCPH) reported revenue of $1.638 million, surpassing market expectations. However, the company also revealed a net deficit of $-14.154 million during the same period, a larger deficit compared to the previous year. These financial results highlight the challenges faced by SCPH in recent times. Let's dive deeper into the context of these results and evaluate SCPH's current market performance.
Financial Snapshot
Despite the positive revenue figure, the net deficit reported by SCPH during the second quarter of 2023 paints a less optimistic picture. The $14.154 million net deficit is significantly higher than ...

Scpharmaceuticals Inc Reports $2.063 Million in Revenue for Fiscal Period Ending March 31, 2023

Scpharmaceuticals Inc Reports Financial Results for Fiscal Period Ending March 31 2023
Scpharmaceuticals Inc (SCP) has recently released its financial results for the fiscal period ending March 31, 2023. The company reported a revenue of $2.063 million. However, it also realized a net shortfall of $-11.210 million, which is a bigger loss than $-7.731 million in the same period a year ago. This figure shows that the company's expenses were higher than their revenues, leading to a significant net loss.
SCP is a biopharmaceutical company that specializes in developing and commercializing pharmaceutical products for the treatment of cardiovascular diseases. The company's lead product, Furoscix, is a subc...


Date modified: 2023-11-10T00:30:06+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com